glp-1 benefits and risks Agonists: Using Semaglutide, Tirzepatide, Orforglipron for Weight Loss and Obesity GLP-1 Receptor Agonists: A Promising

At Nulife Health & Wellness, your safety and comfort are our highest priorities, and we thoroughly evaluate the suitability of GLP-1 receptor agonists based on your personal medical history, health goals, and lifestyle

Glucagon-like peptide-1 receptor agonists (#GLP1s) are associated with a reduced overall cancer risk in adults with obesity, lowering the risk for endometrial, ovarian, and meningioma cancers, while potentially increasing the risk for kidney cancer

Starting at lower doses and titrating slowlyunder provider guidancemay reduce intolerance and improve adherence to treatment

Metformin and the risk of neurodegenerative diseases in patients with diabetes: a meta-analysis of population-based cohort studies

Clinical Evidence on Weight Rebound After Treatment Stops The STEP trials, which evaluated semaglutide efficacy, included a follow-up phase where participants stopped medication

Leading companies such as Novo Nordisk, Eli Lilly, and Sanofi have contributed to market growth with innovative products, including once-weekly formulations to improve patient adherence